47 completed, 16 unknown, 10 recruiting, 4 not yet recruiting. 86 Phase 2, 15 Phase 1, 10 Phase 3.
Follow Erectile Dysfunction: new trials by email Literature Review of Erectile Dysfunction trials Research Report on Erectile Dysfunction
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy of Intracavernosal Xeomin With Tadalafil for Mild-Moderate Erectile Dysfunction IncobotulinumtoxinA (100 Units), Placebo, Tadalafil 20 MG - Erectile Dysfunction | Phase 2 | Not yet recruiting | Northwestern University | 30 | 2026-09-01 | 2026-08-14 |
| Multimodal Prehabilitation and Rehabilitation for Men Undergoing Robot-Assisted Radical Prostatectomy Tadalafil 5 mg, Pelvic Floor Muscle Training (PFMT), Aerobic Exercise Program - Erectile Dysfunction Following Radical Prostatectomy, Prostate Cancer | Phase 2 | Recruiting | Surgical Outcomes Research Centre (SOuRCe) | 64 | 2026-08-31 | 2026-10-23 |
| Stem Cells for Erectile Dysfunction Post RALP Allogeneic adipose-derived mesenchymal stem cells (HB-adMSCs) at the doctor's office, Allogeneic adipose-derived mesenchymal stem cells (HB-adMSCs) in the OR, Placebo in the OR - Erectile Dysfunction, Prostate Cancer | Phase 1 / Phase 2 | Recruiting | The Methodist Hospital Research Institute | 40 | 2026-07-07 | 2026-07-10 |
| A Single-Arm, Dose Escalation of an Intraurethral Alprostadil Paste for Erectile Dysfunction ST-04 - Erectile Dysfunction (ED), Erectile Dysfunctions | Phase 2 | Recruiting | Ryan Flannigan, MD | 83 | 2026-05-01 | 2026-05-22 |
| Effect of Moderate Alcohol on Absorption and Onset of Hezkue Sildenafil Suspension Hezkue Sildenafil Oral Suspension, Moderate Alcohol Intake - Erectile Dysfunction | Phase 2 | Not yet recruiting | Aspargo Labs, Inc | 36 | 2026-04-15 | 2025-12-18 |
| TRIal of STatin Therapy Effect on Androgen Status and Erectile functioN in Men Pitavastatin 1-4 mg daily, Rosuvastatin 20-40 mg daily - Erectile Dysfunction Due to Arterial Disease, Atheroscleroses | Phase 2 | Recruiting | Lomonosov Moscow State University Medical Research and Educational Center | 150 | 2026-03-05 | 2026-03-16 |
| Phase IIa Clinical Trial of YN001 in Patients With Atherosclerotic Cardiovascular and Cerebrovascular Diseases and Erectile Dysfunction YN001 20mg Dose + 5% glucose injection, 5% glucose injection - Atherosclerotic Cardiovascular Disease (ASCVD), Erectile Dysfunction | Phase 2 | Recruiting | Beijing Inno Medicine Co., Ltd. | 40 | 2026-02-04 | 2026-09-22 |
| Clinical Trial Investigating the Effect of Exosomes as a Complementary Treatment in Severe to Moderate Erectile Dysfunction exosomes derived from human umbilical cord mesenchymal stem cells, Normal (0.9%) saline - Erectile Dysfunction, Erectile Dysfunction Associated With Type 2 Diabetes Mellitus | Phase 2 | Not yet recruiting | Labbafinejad Medical Center | 70 | 2026-01-01 | 2026-01-06 |
| Phase 2 Efficacy Study of Sildenafil Products in Adult Men With Erectile Dysfunction Hezkue, Hezkue Turbo, Galotam - Erectile Dysfunction | Phase 2 | Not yet recruiting | Aspargo Labs, Inc | 200 | 2026-01-01 | 2025-11-19 |
| Mesenchymal Stem Cell and Exosome Therapy for Diabetic Erectile Dysfunction Umbilical Cord-Derived Mesenchymal Stem Cells, Umblical Cord-Derived Mesenchymal Stem Cell-Derived Exosomes, Placebo Intracavernosal Injection - Erectile Dysfunction With Diabetes Mellitus | Phase 2 / Phase 3 | Recruiting | Ankara City Hospital Bilkent | 90 | 2025-12-29 | 2026-03-18 |
| A Randomized Double-Blind Clinical Study of Intracavernosal OnabotulinumtoxinA Injection in Patients With Erectile Dysfunction Refractory to Phosphodiesterase-5 Inhibitors OnabotulinumtoxinA (Botox ®) Injections, Saline (0.9% NaCl) - Erectile Dysfunction | Phase 2 | Completed | Clinica Universidad de Navarra, Universidad de Navarra | 114 | 2024-11-25 | 2026-09-22 |
| Phase 2a Trial to Investigate the Efficacy of LIB-01 in Treatment of Erectile Dysfunction LIB-01, LIB-01 Placebo - Erectile Dysfunction | Phase 2 | Completed | Dicot AB | 156 | 2024-11-08 | 2025-08-24 |
| A Prospective Comparative Study of Autologous Bone Marrow-Derived and Adipose Tissue-Derived Mesenchymal Stem Cells Versus Platelet-Rich Plasma and Standard Therapy in Patients With Organic Erectile Dysfunction Autologous Bone marrow-derived Mesenchymal Stem Cells (BMSC), Autologous Platelet-Rich Plasma (4 mL), Autologous Platelet-Rich Plasma (6 mL) - Erectile Dysfunction | Phase 2 | Active not recruiting | National Scientific Medical Center, Kazakhstan | 100 | 2024-09-09 | 2026-04-22 |
| Erectile Dysfunction Treatment Using Stem Cells UC-MSCs and PRP - Erectile Dysfunction | Phase 1 / Phase 2 | Unknown | COR clinic of Regenerative Medicine | 30 | 2024-08-10 | 2024-08-13 |
| Comparsion of Effect of PRP,PDE5 Inhibitor in Treatment of Erectile Dysfunction Tadalafil 5mg - Erectile Dysfunction | Phase 2 / Phase 3 | Completed | Ain Shams University | 75 | 2024-01-15 | 2026-08-12 |
| Safety and Efficacy Evaluation of BZ371A Topically Applied on Prostatectomized Patients Tadalafil 5mg, BZ371A, Oral Placebo - Erectile Dysfunction Following Radical Prostatectomy, Erectile Dysfunction | Phase 2 | Recruiting | Biozeus Biopharmaceutical S.A. | 72 | 2023-11-22 | 2024-10-22 |
| Radiological Evaluation of the Penis Before and After a Botox Injection Injection of Botulinum neurotoxin (BoNT), Penile duplex and shear wave elastosonography (SWE). - Erectile Dysfunction | Phase 1 / Phase 2 | Unknown | Cairo University | 32 | 2023-06-01 | 2023-09-21 |
| Efficacy of Tadalafil (5mg) For Treatment of Early Storage Symptoms and Erectile Dysfunction After Endoscopic Enucleation of Prostate Tadalafil 5mg / Placebo - Erectile Dysfunction, Lower Urinary Tract Symptoms | Phase 2 / Phase 3 | Recruiting | Mansoura University | 110 | 2023-04-01 | 2025-06-11 |
| DualStim Therapy With or Without Umbilical Cord Derived Wharton's Jelly for Erectile Dysfunction DualStim Therapy, Umbilical cord-derived Wharton's Jelly, Saline - Erectile Dysfunction | Phase 1 / Phase 2 | Unknown | BioIntegrate | 60 | 2023-01-01 | 2022-07-21 |
| LiST Plus PRP Injection Therapy vs LiST Monotherapy for ED Treatment LiST + PRP intracorporeal injection, LiST + Placebo(normal saline intracorporeal injection) - Erectile Dysfunction | Phase 2 / Phase 3 | Unknown | Institute for the Study of Urological Diseases, Greece | 60 | 2022-09-01 | 2022-05-09 |
Showing 20 of 86. Sign in to see all of them.
Prostatic Neoplasms (11) · Sexual Dysfunction, Physiological (7) · Hypogonadism (4) · Atherosclerosis (2) · Cardiovascular Diseases (2) · Impotence, Vasculogenic (2) · Lower Urinary Tract Symptoms (2) · Prostatic Hyperplasia (2) · Rectal Neoplasms (2) · Sexual Dysfunctions, Psychological (2) · Urinary Incontinence (2) · Alzheimer Disease (1) · Autoimmune Diseases (1) · Brain Diseases (1)
Genital Diseases (86) · Genital Diseases, Male (86) · Male Urogenital Diseases (86) · Urogenital Diseases (86) · Mental Disorders (85) · Sexual Dysfunctions, Psychological (84) · Sexual Dysfunction, Physiological (79) · Neoplasms (15) · Neoplasms by Site (15) · Prostatic Diseases (12) · Urogenital Neoplasms (12) · Genital Neoplasms, Male (11) · Endocrine System Diseases (6) · Pathological Conditions, Signs and Symptoms (6) · Signs and Symptoms (5)
Tadalafil (10) · Sildenafil Citrate (7) · Sodium Chloride (5) · Vardenafil Dihydrochloride (4) · Botulinum Toxins, Type A (3) · Lipectomy (3) · Saline Solution (3) · udenafil (3) · Injections (2) · fispemifene (2) · mirabegron (2) · 1-((1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidin-3-yl)carbonyl)-3,5-dimethyl-4-phenylpiperidin-4-ol (1) · 1-(6-ethoxy-5-(3-ethyl-6,7-dihydro-2-(2-methoxyethyl)-7-oxo-2H-pyrazolo(4,3-d)pyrimidin-5-yl)-3-pyridyl sulphonyl)-4-ethylpiperazine (1) · 2-(5-(4-(2-hydroxyethyl)piperazin-1-ylsulfonyl)-2-n-propoxyphenyl)-5-ethyl-7-n-propyl-3,5-dihydro-4H-pyrrolo(3,2-d)pyrimidin-4-one dihydrochloride (1) · 4-Aminopyridine (1)
Pfizer (4) · Bayer (3) · Johns Hopkins University (3) · Mansoura University (3) · Ain Shams University (2) · Aspargo Labs, Inc (2) · Benha University (2) · Cairo University (2) · Eli Lilly and Company (2) · Initiator Pharma (2) · Vigonvita Life Sciences (2) · Ageless Regenerative Institute (1) · American Medical Systems (1) · Ankara City Hospital Bilkent (1) · Assistance Publique - Hôpitaux de Paris (1)
United States (25) · Egypt (8) · China (5) · Canada (4) · France (4) · South Korea (4) · United Kingdom (4) · Spain (3) · Brazil (2) · Germany (2) · Israel (2) · Italy (2) · Netherlands (2) · Norway (2) · Russia (2)
Abdelrahman A Hassan, Msc (1) · Ahmed M. Asmy, MD (1) · Ahmed Shokeir, PhD (1) · Alvaro Morales, MD FRCSC (1) · Andre-Guy Martin, MD (1) · Andrew Herzog, M.D., M.Sc. (1) · Andrey A Pulin, MD, PhD (1) · Anne Yee (1) · Antonella Favit-Van Pelt, MD, PhD (1) · Arthur Burnett, MD (1) · Arthur L Burnett, M.D., M.B.A. (1) · Ashim Gupta, PhD, MBA (1) · Barbara Troupin, MD, MBA (1)
PMID 25974235, PMID 11121838, PMID 16528082, PMID 19473458, PMID 24468580, PMID 26158605, PMID 26439886, PMID 28480661, PMID 28753830, PMID 31099420, PMID 33530745, PMID 34326007, PMID 35448895, PMID 37993601, PMID 38224135, PMID 38729561, PMID 38773595, PMID 40830783, PMID 40971935, PMID 42114123, PMID 42725809
U10CA081851 (1)